Sol-Gel Technologies (NASDAQ:SLGL – Get Rating) had its target price hoisted by HC Wainwright from $20.00 to $21.00 in a research report issued on Monday, The Fly reports. HC Wainwright’s price objective indicates a potential upside of 185.33% from the stock’s current price.
SLGL has been the topic of several other research reports. Raymond James reduced their price objective on shares of Sol-Gel Technologies from $21.00 to $17.00 and set a “strong-buy” rating on the stock in a research report on Friday, April 1st. Zacks Investment Research cut shares of Sol-Gel Technologies from a “strong-buy” rating to a “hold” rating in a research report on Thursday.
Shares of Sol-Gel Technologies stock opened at $7.36 on Monday. The firm has a market cap of $150.07 million, a price-to-earnings ratio of 56.62 and a beta of 1.17. Sol-Gel Technologies has a 1 year low of $6.12 and a 1 year high of $14.80. The company has a 50-day moving average of $7.30 and a 200 day moving average of $7.74.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Raymond James Financial Services Advisors Inc. raised its position in Sol-Gel Technologies by 6.2% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 129,011 shares of the company’s stock valued at $1,288,000 after purchasing an additional 7,544 shares in the last quarter. Raymond James & Associates increased its position in Sol-Gel Technologies by 14.1% during the 3rd quarter. Raymond James & Associates now owns 36,608 shares of the company’s stock valued at $365,000 after purchasing an additional 4,519 shares during the period. Susquehanna International Group LLP increased its position in Sol-Gel Technologies by 34.0% during the 4th quarter. Susquehanna International Group LLP now owns 16,862 shares of the company’s stock valued at $125,000 after purchasing an additional 4,275 shares during the period. Finally, We Are One Seven LLC purchased a new position in Sol-Gel Technologies during the 4th quarter valued at about $74,000. 28.79% of the stock is owned by institutional investors.
Sol-Gel Technologies Company Profile (Get Rating)
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions.
- Get a free copy of the StockNews.com research report on Sol-Gel Technologies (SLGL)
- Schwab Stock Can Be Caught Down Here
- Snap Up Some Snap-On On Post-Earnings Weakness
- Time to Buy any Dip in Prologis Stock
- 3 Resilient Stocks to Buy for Retirement
- MarketBeat: Week in Review 4/18 – 4/22
Receive News & Ratings for Sol-Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol-Gel Technologies and related companies with MarketBeat.com's FREE daily email newsletter.